DDIT3 and diffuse large B-cell lymphoma: In the PHOENIX trial (25), the CRR was 64.9% in the DE-DLBCL patients treated with R-CHOP (similar to 65.2% in this study), and 67.5% in those treated with ibrutinib plus R-CHOP.